IRIS PubliCatt

Fabbiani, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3501
NA - Nord America 2550
AS - Asia 586
AF - Africa 7
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 6658
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2526
DE - Germania 1187
SE - Svezia 585
PL - Polonia 427
CN - Cina 423
FR - Francia 397
UA - Ucraina 325
IT - Italia 294
GB - Regno Unito 117
FI - Finlandia 85
IN - India 82
TR - Turchia 45
BE - Belgio 32
CA - Canada 19
IR - Iran 18
RU - Federazione Russa 12
JP - Giappone 8
EU - Europa 6
NL - Olanda 6
MX - Messico 5
BR - Brasile 4
DK - Danimarca 4
AT - Austria 3
CH - Svizzera 3
CZ - Repubblica Ceca 3
IE - Irlanda 3
RO - Romania 3
BG - Bulgaria 2
EG - Egitto 2
ES - Italia 2
KR - Corea 2
NO - Norvegia 2
PH - Filippine 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
EE - Estonia 1
HK - Hong Kong 1
HR - Croazia 1
HU - Ungheria 1
IM - Isola di Man 1
IS - Islanda 1
KE - Kenya 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MA - Marocco 1
NG - Nigeria 1
PE - Perù 1
PK - Pakistan 1
SG - Singapore 1
UG - Uganda 1
Totale 6658
Salva come PNG Salva come JPEG
Città #
Chandler 654
Kraków 426
Jacksonville 247
San Mateo 156
Nanjing 135
Ann Arbor 122
Ashburn 87
Dearborn 85
Nürnberg 83
Wilmington 76
Houston 74
Lawrence 71
Cattolica 66
Woodbridge 62
Nanchang 57
Lancaster 53
Milan 51
Redmond 50
Boston 48
Izmir 45
Redwood City 42
Shenyang 33
Brussels 32
Seattle 31
Boardman 25
Bremen 25
Kunming 25
Verona 24
Changsha 23
Mountain View 23
Fairfield 22
Hebei 22
Norwalk 21
Rome 21
Falls Church 20
Munich 19
Leawood 17
University Park 17
Marseille 15
Shanghai 15
Beijing 14
Tianjin 14
Augusta 13
Hangzhou 13
Jinan 13
Ottawa 13
Fremont 12
New York 10
Guangzhou 9
Simi Valley 9
Princeton 8
Zhengzhou 8
Cambridge 7
Changchun 7
Helsinki 7
Jiaxing 7
Chicago 6
Detroit 6
Edinburgh 6
Kish 6
Andover 5
Hefei 5
Costa Mesa 4
Los Angeles 4
Philadelphia 4
Sacramento 4
Toronto 4
Ardabil 3
Auburn Hills 3
Fuzhou 3
Gustavo Adolfo Madero 3
Indiana 3
Latina 3
Modena 3
Omsk 3
Phoenixville 3
Amsterdam 2
Anzio 2
Barcelona 2
Bari 2
Berlin 2
Bologna 2
Chengdu 2
Chongqing 2
Clearwater 2
Faenza 2
Formia 2
Genzano di Roma 2
Groningen 2
Henderson 2
Kashan 2
Lanzhou 2
Lequile 2
London 2
New Delhi 2
Ozzano Monferrato 2
Paris 2
Phoenix 2
San Francisco 2
San Jose 2
Totale 3413
Salva come PNG Salva come JPEG
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 185
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 159
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 157
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 157
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 147
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 137
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 133
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 133
IL PRIVATO SOCIALE: UN'OPPORTUNITÀ PER I PAZIENTI E PER LE STRUTTURE SANITARIE NELL'ATTUALE CONTESTO ECONOMICO 133
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 129
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 124
Variability of raltegravir plasma levels in the clinical setting 114
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 113
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 112
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 108
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 107
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 107
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 102
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 101
Initial antifungal strategy does not correlate with mortality in patients with candidemia 99
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 97
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 96
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 94
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 93
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 92
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 91
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 91
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 90
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 88
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 88
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 87
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 86
Immune response to influenza A(H1N1)v in HIV-infected patients 85
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? 85
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 85
Cognitive reserve and neuropsychological functioning in older HIV-infected people 85
Effect of aging and human immunodeficiency virus infection on cognitive abilities 84
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 84
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 83
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 83
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 83
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 82
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 81
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 81
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 80
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data. 79
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 79
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 75
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 75
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 74
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 74
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 74
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 72
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 70
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 70
Immune response to influenza A(H1N1)v in HIV-infected patients 69
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 67
Lipid-lowering effect of tenofovir in HIV-infected patients 67
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 65
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 64
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 63
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 60
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 60
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 60
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 59
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 57
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 57
null 54
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 52
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort 49
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 47
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 46
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 46
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 44
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART 41
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 38
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 34
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received 29
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 23
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 9
Totale 6733
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12855
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12855
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018165 0000 00 00 008976
2018/2019838 334724110 159120 11829 27468342
2019/2020955 226466433 86103 4944 69619381
2020/2021696 4186774 8537 7616 1152212116
2021/2022806 77642561 4740 21129 2973121119
2022/20231639 237261132258 136191 32152 19514310
Totale 6733